Genentech, CDER Spar Over Third-Party Views On Avastin Breast Cancer Claim

Disagreements between Genentech and FDA’s Center for Drug Evaluation and Research over the scope of evidence to be allowed at the June 28-29 hearing on Avastin’s breast cancer indication have escalated into a heated debate over the relevance of external views.